NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against STAAR Surgical Company (NASDAQ:STAA) resulting from allegations that the Company may have made false and misleading disclosures concerning its business operations and prospects.
On July 1, 2014, the U.S. Food and Drug Administration (“FDA”) released publicly a warning letter it had sent to STAAR Surgical on May 21, 2014. The warning letter stated that the Company's Monrovia, California facility lacks adequate procedures for documenting design of implantable lenses for the eye. The FDA also cited failures in handling complaints, sterility testing, and keeping required records. The FDA’s findings stem from inspections in February-March 2014.
The Rosen Law Firm is preparing a class action lawsuit on behalf of STAAR Surgical investors. If you purchased STAAR Surgical securities prior to July 1, 2014, you may visit the website at http://rosenlegal.com to join the action. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at email@example.com or firstname.lastname@example.org.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.